Clinical trials: Second Cancer, open to volunteers
Breast Cancer
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Prospective, multi-center, randomized, open label comparative Phase III study in patients with intermediate to high-risk (as defined in the SURVIVE trial) HER2-positive or HER2-low early breast cancer, who participate in the…
- Trial name
- SURVIVE HERoes (NCT06643585)
- Testing
- Trastuzumab-Deruxtecan, Physicians Choice (PhC).
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- Prof. Wolfgang Janni
Colorectal Cancer (CRC)
Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer
This study is divided into two phases. The first phase aims to preliminarily evaluate the efficacy and safety of fruquintinib in combination with irinotecan liposome and capecitabine as second-line therapy for advanced metastatic…
- Trial name
- ARK (NCT07051785)
- Testing
- Fruquintinib+Irinotecan Liposome+Capecitabine, Bevacizumab+Irinotecan Liposome+Capecitabine
- Volunteers
- 68 people
- Sponsor
- Liu Huang